Index -
P/E -
EPS (ttm) -1.14
Insider Own 22.86%
Shs Outstand 36.83M
Perf Week -30.94%
Market Cap 158.55M
Forward P/E -
EPS next Y -0.93
Insider Trans 86.39%
Shs Float 30.96M
Perf Month 49.06%
Income -58.21M
PEG -
EPS next Q -0.32
Inst Own 60.94%
Short Float 2.63%
Perf Quarter 121.91%
Sales 0.00M
P/S -
EPS this Y -17.70%
Inst Trans -0.33%
Short Ratio 1.39
Perf Half Y 333.92%
Book/sh 1.77
P/B 2.24
EPS next Y 22.19%
ROA -52.46%
Short Interest 0.81M
Perf Year 99.49%
Cash/sh 1.99
P/C 1.98
EPS next 5Y -
ROE -58.75%
52W Range 0.72 - 6.10
Perf YTD 297.98%
Dividend Est. -
P/FCF -
EPS past 5Y 48.08%
ROI -80.09%
52W High -35.24%
Beta 1.23
Dividend TTM -
Quick Ratio 11.82
Sales past 5Y 0.00%
Gross Margin -
52W Low 448.61%
ATR (14) 0.57
Dividend Ex-Date -
Current Ratio 11.82
EPS Y/Y TTM -6.90%
Oper. Margin 0.00%
RSI (14) 47.19
Volatility 9.91% 14.25%
Employees 51
Debt/Eq 0.03
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 10.57
Option/Short Yes / Yes
LT Debt/Eq 0.03
EPS Q/Q -10.10%
Payout -
Rel Volume 7.39
Prev Close 5.16
Sales Surprise -
EPS Surprise -12.81%
Sales Q/Q -
Earnings May 15 AMC
Avg Volume 583.92K
Price 3.95
SMA20 -5.64%
SMA50 16.48%
SMA200 123.13%
Trades
Volume 4,312,476
Change -23.45%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-04-24 Initiated
Craig Hallum
Buy
$14
Apr-09-24 Initiated
Maxim Group
Buy
$8
Aug-02-22 Resumed
Canaccord Genuity
Buy
$17
Jun-15-22 Initiated
Cantor Fitzgerald
Overweight
$9
Sep-08-21 Initiated
ROTH Capital
Buy
$21
May-27-21 Initiated
Oppenheimer
Outperform
$25
May-25-21 Initiated
H.C. Wainwright
Buy
$21
Jun-14-24 07:30AM
Jun-13-24 11:30PM
04:01PM
May-30-24 08:00AM
May-22-24 07:23AM
06:27AM
Loading…
06:27AM
May-21-24 04:05PM
May-15-24 10:54PM
04:05PM
Apr-23-24 08:00AM
Mar-20-24 02:33PM
Mar-06-24 07:30AM
Feb-13-24 04:05PM
Jan-24-24 08:00AM
Jan-23-24 08:00AM
08:00AM
Loading…
Dec-14-23 08:00AM
Dec-13-23 08:00AM
Nov-24-23 11:14AM
Nov-17-23 08:00AM
Nov-13-23 04:05PM
Oct-17-23 08:00AM
Oct-11-23 08:00AM
Sep-14-23 04:05PM
Sep-06-23 07:00AM
Jun-27-23 04:05PM
Jun-01-23 12:45PM
May-11-23 04:05PM
Mar-23-23 04:50PM
Mar-08-23 07:00AM
Feb-10-23 04:05PM
07:00AM
Loading…
Dec-15-22 07:00AM
Nov-09-22 04:05PM
Nov-01-22 07:00AM
Oct-20-22 07:00AM
Sep-15-22 04:05PM
Sep-07-22 07:00AM
Aug-15-22 08:36AM
Jun-01-22 07:00AM
May-12-22 04:05PM
May-04-22 04:01PM
09:33AM
May-01-22 11:25PM
02:00PM
Apr-26-22 04:05PM
Mar-29-22 07:00AM
Mar-23-22 07:00AM
Feb-22-22 07:00AM
Feb-09-22 04:05PM
Nov-12-21 04:05PM
Oct-19-21 12:14PM
Oct-13-21 08:10AM
Oct-12-21 04:05PM
Sep-22-21 04:05PM
Sep-15-21 04:56PM
Sep-09-21 04:05PM
Sep-07-21 04:05PM
Aug-10-21 07:00AM
Aug-03-21 07:00AM
Jun-28-21 07:00AM
Jun-24-21 09:01PM
Jun-03-21 05:35AM
May-31-21 10:17AM
May-27-21 07:00AM
May-20-21 07:00AM
May-18-21 07:00AM
May-17-21 04:05PM
07:00AM
May-04-21 08:00AM
Apr-19-21 08:00AM
Mar-22-21 08:00AM
Mar-08-21 08:00AM
Mar-02-21 05:16PM
Feb-10-21 04:05PM
Jan-12-21 08:30AM
Jan-11-21 07:56AM
Dec-28-20 04:05PM
Dec-03-20 08:00AM
Nov-19-20 08:00AM
Nov-05-20 08:00AM
Oct-09-20 08:30AM
Sep-10-20 08:00AM
Jul-27-20 08:00AM
Jun-15-20 08:30AM
May-28-20 08:30AM
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperinsulinism, AB101-Phase 1, a once-weekly injectable basal insulin, and RZ402, which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Evans Daron CFO Jun 14 '24 Buy 4.04 40,000 161,568 40,000 Jun 14 12:06 PM ROBERTS BRIAN KENNETH Chief Medical Officer Jun 14 '24 Buy 3.91 4,300 16,828 54,352 Jun 14 12:51 PM ROBERTS BRIAN KENNETH Chief Medical Officer Jun 14 '24 Buy 3.91 3,300 12,916 13,000 Jun 14 12:51 PM Evans Daron CFO May 29 '24 Buy 3.50 451 1,578 121,351 May 31 04:05 PM Evans Daron CFO May 24 '24 Buy 3.23 2,942 9,503 13,000 May 28 02:48 PM ROBERTS BRIAN KENNETH Chief Medical Officer May 23 '24 Buy 2.69 7,500 20,138 50,052 May 28 02:56 PM Evans Daron CFO May 23 '24 Buy 2.85 58 165 10,058 May 28 02:48 PM ROBERTS BRIAN KENNETH Chief Medical Officer Mar 28 '24 Buy 2.55 500 1,275 1,076 Mar 29 11:08 AM Evans Daron CFO Mar 15 '24 Buy 1.69 20,000 33,830 20,000 Mar 19 09:17 AM ROBERTS BRIAN KENNETH Chief Medical Officer Mar 14 '24 Buy 1.88 10,000 18,800 10,000 Mar 18 11:20 AM Evans Daron CFO Mar 08 '24 Buy 1.93 50,000 96,345 120,900 Mar 08 12:37 PM Kim Young-Jin Director Mar 07 '24 Buy 1.91 36,503 69,859 115,450 Mar 14 10:35 AM ROBERTS BRIAN KENNETH Chief Medical Officer Mar 07 '24 Buy 1.85 500 925 500 Mar 11 10:35 AM Elam Nevan C CEO Feb 26 '24 Buy 1.68 5,000 8,400 7,817 Feb 28 11:40 AM ROBERTS BRIAN KENNETH Chief Medical Officer Feb 26 '24 Buy 1.70 2,000 3,400 42,552 Feb 27 08:47 AM ROBERTS BRIAN KENNETH Chief Medical Officer Feb 23 '24 Buy 1.69 6,000 10,140 40,552 Feb 27 08:47 AM Evans Daron CFO Feb 16 '24 Buy 1.30 41,900 54,411 70,900 Feb 20 07:01 AM Evans Daron CFO Feb 16 '24 Buy 1.37 9,000 12,330 4,500 Feb 20 07:01 AM ROBERTS BRIAN KENNETH Chief Medical Officer Feb 16 '24 Buy 1.31 7,000 9,142 34,552 Feb 21 11:55 AM ROBERTS BRIAN KENNETH Chief Medical Officer Jul 03 '23 Buy 1.90 5,000 9,500 27,552 Jul 06 11:18 AM
Index RUT
P/E -
EPS (ttm) -0.38
Insider Own 47.39%
Shs Outstand 138.14M
Perf Week 3.03%
Market Cap 563.82M
Forward P/E -
EPS next Y -0.42
Insider Trans -0.29%
Shs Float 72.70M
Perf Month -15.53%
Income -64.49M
PEG -
EPS next Q -0.11
Inst Own 46.15%
Short Float 7.76%
Perf Quarter -13.38%
Sales 0.00M
P/S -
EPS this Y -25.54%
Inst Trans 2.91%
Short Ratio 6.41
Perf Half Y -6.42%
Book/sh 0.88
P/B 4.63
EPS next Y -2.07%
ROA -44.84%
Short Interest 5.64M
Perf Year 27.50%
Cash/sh 1.04
P/C 3.94
EPS next 5Y -
ROE -58.59%
52W Range 2.60 - 5.70
Perf YTD -13.19%
Dividend Est. -
P/FCF -
EPS past 5Y 29.09%
ROI -43.49%
52W High -28.42%
Beta 1.00
Dividend TTM -
Quick Ratio 14.90
Sales past 5Y -20.00%
Gross Margin -
52W Low 56.92%
ATR (14) 0.24
Dividend Ex-Date -
Current Ratio 14.90
EPS Y/Y TTM -42.50%
Oper. Margin 0.00%
RSI (14) 43.36
Volatility 6.23% 5.50%
Employees 37
Debt/Eq 0.22
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 9.00
Option/Short Yes / Yes
LT Debt/Eq 0.22
EPS Q/Q -61.22%
Payout -
Rel Volume 0.77
Prev Close 4.06
Sales Surprise -
EPS Surprise -11.56%
Sales Q/Q -
Earnings May 09 AMC
Avg Volume 880.08K
Price 4.08
SMA20 -2.18%
SMA50 -10.32%
SMA200 -5.58%
Trades
Volume 681,183
Change 0.49%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-15-24 Initiated
JMP Securities
Mkt Outperform
$8
Nov-07-23 Initiated
Guggenheim
Buy
$7
May-16-23 Upgrade
Jefferies
Hold → Buy
$2 → $4
Mar-31-23 Downgrade
Jefferies
Buy → Hold
$2
Mar-16-21 Initiated
Piper Sandler
Overweight
$7
Mar-15-21 Initiated
Oppenheimer
Outperform
$4
Jun-13-19 Reiterated
H.C. Wainwright
Buy
$22 → $6
Jun-13-19 Downgrade
Ladenburg Thalmann
Buy → Neutral
$21 → $3
Jun-13-19 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
Aug-13-18 Resumed
ROTH Capital
Neutral
$12
Jan-03-18 Initiated
Ladenburg Thalmann
Buy
$35
Sep-27-17 Resumed
ROTH Capital
Buy
$40
Sep-22-17 Initiated
Jefferies
Buy
$20
Sep-11-17 Initiated
JMP Securities
Mkt Outperform
$20
Show Previous Ratings
Jun-11-24 06:00AM
May-29-24 08:05AM
May-21-24 08:20AM
May-19-24 12:15PM
May-16-24 04:05PM
10:55PM
Loading…
May-09-24 10:55PM
04:05PM
May-07-24 04:05PM
Apr-08-24 08:05AM
Mar-22-24 04:05PM
Mar-07-24 10:54PM
04:05PM
Mar-06-24 04:05PM
Feb-02-24 08:05AM
Jan-31-24 08:05AM
03:01PM
Loading…
Dec-30-23 03:01PM
Dec-21-23 08:05AM
Dec-20-23 08:05AM
Dec-15-23 04:05PM
Nov-21-23 08:05AM
Nov-09-23 04:05PM
Nov-08-23 04:05PM
Oct-06-23 04:05PM
Sep-27-23 07:29PM
Sep-17-23 10:54AM
Sep-12-23 09:12AM
Sep-05-23 04:05PM
Aug-10-23 04:05PM
Aug-04-23 04:05PM
Jul-13-23 07:00AM
04:05PM
Loading…
Jun-26-23 04:05PM
08:05AM
Jun-02-23 08:05AM
May-28-23 08:26AM
May-16-23 12:32PM
May-15-23 08:05AM
May-05-23 04:05PM
Apr-03-23 07:33AM
Mar-31-23 04:05PM
Mar-30-23 04:05PM
Mar-20-23 06:35AM
Mar-17-23 06:47AM
Mar-16-23 06:51AM
Mar-15-23 06:44AM
Mar-13-23 06:32AM
Mar-10-23 07:04AM
Mar-09-23 06:33AM
Mar-08-23 06:30AM
Mar-07-23 06:34AM
Mar-06-23 04:05PM
07:22AM
Mar-03-23 06:38AM
Mar-02-23 06:44AM
Mar-01-23 06:01AM
Feb-28-23 04:05PM
06:43AM
Feb-27-23 06:50AM
Feb-23-23 07:21AM
Feb-22-23 06:56AM
Feb-21-23 07:35AM
Feb-17-23 06:27AM
Feb-16-23 07:28AM
Feb-15-23 07:01AM
06:24AM
Feb-14-23 08:05AM
06:23AM
Feb-13-23 07:30AM
Feb-10-23 06:42AM
Feb-09-23 06:51AM
Feb-08-23 06:45AM
Feb-07-23 06:46AM
Feb-06-23 06:56AM
Feb-03-23 06:32AM
Feb-02-23 06:43AM
Feb-01-23 06:14AM
Jan-31-23 06:50AM
Jan-30-23 06:42AM
Jan-27-23 03:47PM
07:00AM
Jan-26-23 06:44AM
Jan-25-23 06:39AM
Jan-24-23 06:48AM
Jan-23-23 06:58AM
Jan-20-23 08:05AM
06:55AM
Jan-19-23 06:43AM
Jan-18-23 06:28AM
Jan-17-23 06:27AM
Jan-13-23 06:56AM
Jan-12-23 06:50AM
Jan-11-23 06:53AM
Jan-09-23 06:31AM
Jan-06-23 06:49AM
Jan-05-23 05:43AM
Jan-04-23 06:54AM
06:54AM
Jan-03-23 06:26AM
Dec-30-22 07:17AM
Dec-29-22 06:51AM
Dec-27-22 07:11AM
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Elam Nevan C Director Dec 28 '23 Option Exercise 1.30 53,758 69,722 116,343 Dec 29 04:33 PM Elam Nevan C Director Dec 28 '23 Sale 4.71 93,843 442,291 22,500 Dec 29 04:33 PM Pauls Matthew CHIEF EXECUTIVE OFFICER Dec 28 '23 Sale 4.71 84,000 395,900 1,302,674 Dec 29 04:35 PM Lowrance David L CHIEF FINANCIAL OFFICER Dec 28 '23 Sale 4.71 10,000 47,131 342,355 Dec 29 04:34 PM Hawkins Richard J Director Dec 11 '23 Option Exercise 0.82 10,841 8,890 12,741 Dec 12 06:09 PM Elam Nevan C Director Dec 11 '23 Option Exercise 0.82 10,841 8,890 40,085 Dec 12 06:08 PM Chang Carmen 10% Owner Jul 17 '23 Buy 3.00 333,333 999,999 24,471,264 Jul 19 07:07 PM Behbahani Ali 10% Owner Jul 17 '23 Buy 3.00 333,333 999,999 24,471,264 Jul 19 07:06 PM BASKETT FOREST 10% Owner Jul 17 '23 Buy 3.00 333,333 999,999 24,471,264 Jul 19 07:05 PM Growth Equity Opportunities 17 10% Owner Jul 17 '23 Buy 3.00 333,333 999,999 24,471,264 Jul 19 07:04 PM Yang Rick 10% Owner Jul 17 '23 Buy 3.00 333,333 999,999 24,471,264 Jul 19 07:13 PM SANDELL SCOTT D 10% Owner Jul 17 '23 Buy 3.00 333,333 999,999 24,471,264 Jul 19 07:11 PM Walker Paul Edward 10% Owner Jul 17 '23 Buy 3.00 333,333 999,999 24,471,264 Jul 19 07:12 PM Mathers Edward T 10% Owner Jul 17 '23 Buy 3.00 333,333 999,999 24,471,264 Jul 19 07:10 PM Makhzoumi Mohamad 10% Owner Jul 17 '23 Buy 3.00 333,333 999,999 24,471,264 Jul 19 07:09 PM Florence Anthony A. Jr. 10% Owner Jul 17 '23 Buy 3.00 333,333 999,999 24,471,264 Jul 19 07:08 PM Pratt Raymond Dennis Chief Medical Officer Jun 26 '23 Buy 2.93 6,500 19,045 160,000 Jun 27 07:00 AM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite